Molecular Mechanisms of Rett Syndrome: Emphasizing the Roles of Monoamine, Immunity, and Mitochondrial Dysfunction

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Rett syndrome (RTT) predominantly affects females and is primarily caused by mutations in the Methyl-CpG-binding Protein-2 (MECP2) gene.
• Impaired MeCP2 function disrupts gene regulation, leading to dysfunctional proteins and multi-systemic issues in RTT.
• Understanding the molecular underpinnings is crucial for developing effective treatments.

Purpose of the Study:

• To review current insights into molecular signaling pathways implicated in Rett syndrome pathophysiology.
• To explore the roles of monoamine signaling, immune response, and mitochondrial function in RTT.
• To identify potential therapeutic targets based on these molecular disruptions.

Main Methods:

• This is a review article, synthesizing existing research findings.
• Analysis of molecular signaling pathways including monoamines, immune mediators, and mitochondrial function.
• Examination of genetic mutations, specifically in the MECP2 gene, and their downstream effects.

Main Results:

• Alterations in monoamines (dopamine, norepinephrine, serotonin, etc.) contribute to neurological symptoms in RTT.
• Immune system dysfunction is evident, with abnormal immune cell activity and inflammatory mediator release via the NF-κB pathway.
• Mitochondrial dysfunction and disrupted redox balance (reactive oxygen species) are key features of RTT pathophysiology.

Conclusions:

• Molecular signaling pathways, including monoamines, immune responses, and mitochondrial function, are significantly altered in Rett syndrome.
• These disruptions provide a basis for understanding RTT's complex pathophysiology.
• Targeting these specific molecular pathways holds promise for future therapeutic interventions for RTT.